For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication.
As the manufacturer is unable to demonstrate the cost-effectiveness of fampridine we are unable to recommend reimbursement
The NCPE believe that apixaban is cost effective for this indication
Following a price revision we now consider rivaroxaban a cost-effective therapy for this indication.
The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost-effective for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)
We believe that at the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion.
The NCPE believe that, at the submitted price, cabazitaxel is not cost-effective for the treatment of patients with mHRPC previously treated with a docetaxel-containing treatment regimen.
Full Pharmacoeconomic Evaluation Recommended
Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland PCV13 is the most cost-effective option if the analysis is based on a serotype distribution reflecting 2011 data. download document
We consider telaprevir (Incivo®) a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.